- Stocks
- Healthcare
- NASDAQ: AMPH

Price (delayed)

$17.27

Market cap

$819.17M

P/E Ratio

575.67

Dividend/share

N/A

EPS

$0.03

Enterprise value

$791.93M

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.amphastar.com

Amphastar Pharmaceuticals's revenue has increased by 9% YoY and by 3.7% QoQ

The company's gross profit rose by 9% YoY and by 2.5% QoQ

The stock's P/E is 123% more than its last 4 quarters average of 258.3

The EPS has plunged by 97% YoY and by 80% from the previous quarter

What are the main financial stats of AMPH

Market
Valuations
Earnings

Shares outstanding

47.43M

Market cap

$819.17M

Enterprise value

$791.93M

Price to earnings (P/E)

575.67

Price to book (P/B)

2.04

Price to sales (P/S)

2.32

EV/EBIT

148.94

EV/EBITDA

30.69

EV/Sales

2.26

Revenue

$349.85M

EBIT

$5.32M

EBITDA

$25.81M

Free cash flow

$23.41M

Per share
Balance sheet
Liquidity

EPS

$0.03

Free cash flow per share

$0.5

Book value per share

$8.47

Revenue per share

$7.44

TBVPS

$12.56

Total assets

$631.24M

Total liabilities

$182.51M

Debt

$67.27M

Equity

$402.31M

Working capital

$167.48M

Debt to equity

0.17

Current ratio

2.49

Quick ratio

1.57

Net debt/EBITDA

-1.06

Margins
Efficiency
Dividend

EBITDA margin

7.4%

Gross margin

41%

Net margin

0.4%

Operating margin

3.1%

Return on assets

0.2%

Return on equity

0.4%

Return on invested capital

1.2%

Return on capital employed

1%

Return on sales

1.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Amphastar Pharmaceuticals stock price performed over time

Intraday

-0.17%

1 week

0.94%

1 month

-4.43%

1 year

5.69%

YTD

-14.12%

QTD

-5.73%

How have Amphastar Pharmaceuticals's revenue and profit performed over time

Revenue

$349.85M

Gross profit

$143.34M

Operating income

$10.95M

Net income

$1.4M

Gross margin

41%

Net margin

0.4%

The net income has plunged by 97% YoY and by 79% from the previous quarter

AMPH's net margin has dropped by 97% year-on-year and by 80% since the previous quarter

The operating income has increased by 40% since the previous quarter

AMPH's operating margin is up by 35% since the previous quarter

What is Amphastar Pharmaceuticals's growth rate over time

What is Amphastar Pharmaceuticals stock price valuation

P/E

575.67

P/B

2.04

P/S

2.32

EV/EBIT

148.94

EV/EBITDA

30.69

EV/Sales

2.26

The stock's P/E is 123% more than its last 4 quarters average of 258.3

The EPS has plunged by 97% YoY and by 80% from the previous quarter

The price to book (P/B) is 18% lower than the 5-year quarterly average of 2.5 and 11% lower than the last 4 quarters average of 2.3

Amphastar Pharmaceuticals's equity has increased by 5% YoY

AMPH's price to sales (P/S) is 22% less than its 5-year quarterly average of 3.0 and 10% less than its last 4 quarters average of 2.6

Amphastar Pharmaceuticals's revenue has increased by 9% YoY and by 3.7% QoQ

How efficient is Amphastar Pharmaceuticals business performance

The company's return on assets has shrunk by 98% YoY and by 82% QoQ

The ROE has plunged by 97% YoY and by 76% from the previous quarter

The ROS has plunged by 92% YoY and by 57% from the previous quarter

The ROIC has dropped by 92% year-on-year and by 54% since the previous quarter

What is AMPH's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for AMPH.

How did Amphastar Pharmaceuticals financials performed over time

AMPH's total liabilities is up by 14% year-on-year and by 12% since the previous quarter

Amphastar Pharmaceuticals's current ratio has decreased by 13% from the previous quarter and by 12% YoY

AMPH's debt is 83% smaller than its equity

Amphastar Pharmaceuticals's debt to equity has increased by 6% from the previous quarter

Amphastar Pharmaceuticals's equity has increased by 5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.